Author

B. Moss

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 6 Organism:mouse· 4 Research Focus:cell type annotation· 2 Organism:human· 2 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. L. Americo· 4 shared P. L. Earl· 4 shared C. A. Cotter· 3 shared C. Peng· 2 shared A. Carfi· 1 shared A. Nasir· 1 shared A. W. Freyn· 1 shared C. Atyeo· 1 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

J. L. Americo

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Human FAM111A inhibits vaccinia virus replication by degrading viral DNA-binding protein I3 and is antagonized by poxvirus host range factor SPI-1

J. Zhu, X. Gao, Z. Zhang, Y. Deng, S. Xie, S. Ren, Y. Li, H. Li, K. Niu, S. Fu, Y. Li, B. Moss, W. Wu, C. Peng

This study identifies FAM111A as a restriction factor for vaccinia virus and MVA, showing it degrades viral DNA-binding protein I3 and is counteracted by SPI-1.

Proceedings of the National Academy of Sciences · Aug 29, 2023Peer-reviewedMicrobiology

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss

This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.

bioRxiv · Dec 17, 2022 · PreprintImmunology

Enhanced Protection from SARS-CoV-2 Variants by MVA-Based Vaccines Expressing Matched or Mismatched S Proteins Administered Intranasally to hACE2 Mice

C. A. Cotter, J. L. Americo, P. L. Earl, B. Moss

This study evaluates MVA-based vaccines with matched or mismatched S proteins against SARS-CoV-2 variants in hACE2 mice, showing that mismatched vaccines still provide protection, especially when administered intranasally.

bioRxiv · Dec 3, 2022 · PreprintMicrobiology

Virulence Differences of Monkeypox Virus Clades 1, 2a and 2b.1 in a Small Animal Model

J. L. Americo, P. L. Earl, B. Moss

This study compares the virulence of three monkeypox virus clades in a mouse model, finding clade 1 > clade 2a > clade 2b.1 in severity.

bioRxiv · Dec 1, 2022 · PreprintMicrobiology

Exaptation of inactivated host enzymes for structural roles in orthopoxviruses and novel protein folds revealed by protein structure modeling

P. Mutz, W. Resch, G. Faure, T. G. Senkevich, E. V. Koonin, B. Moss

The paper uses AlphaFold2 to predict structures of orthopoxvirus proteins, revealing exaptation of inactivated host enzymes for structural roles and novel protein folds.

bioRxiv · Nov 22, 2022 · PreprintMicrobiology

Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry

L. Priyamvada, W. W. Kallemeijn, M. Faronato, K. Wilkins, C. S. Goldsmith, C. A. Cotter, S. Ojeda, R. Solari, B. Moss, E. W. Tate, P. S. Satheshkumar

This study shows that IMP-1088 inhibits vaccinia virus infection by blocking N-myristoylation of viral protein L1, leading to non-infectious virions.

bioRxiv · Jun 13, 2022Microbiology

MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease

R. Liu, J. L. Americo, C. A. Cotter, P. L. Earl, N. Erez, C. Peng, B. Moss

This study shows that recombinant MVA vaccines expressing modified S proteins inhibit SARS-CoV-2 replication and prevent lethal disease in transgenic mice.

bioRxiv · Dec 30, 2020 · PreprintMicrobiology